Modality
ADC
MOA
FcRni
Target
PLK4
Pathway
Hedgehog
Bladder CaAlzheimer'sCSU
Development Pipeline
Preclinical
~Dec 2015
→ ~Mar 2017
Phase 1
~Jun 2017
→ ~Sep 2018
Phase 2
~Dec 2018
→ ~Mar 2020
Phase 3
~Jun 2020
→ ~Sep 2021
NDA/BLA
Dec 2021
→ Jul 2027
NDA/BLACurrent
NCT04552245
332 pts·Bladder Ca
2021-12→2027-07·Terminated
332 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-07-121.3y awayPh3 Readout· Bladder Ca
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2027-07-12 · 1.3y away
Bladder Ca
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04552245 | NDA/BLA | Bladder Ca | Terminated | 332 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Zanufutibatinib | Intra-Cellular | NDA/BLA | CD38 | |
| Pexaosocimab | United Therapeutics | NDA/BLA | PLK4 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ILM-2412 | Illumina | Phase 3 | PLK4 | |
| ROI-3353 | Roivant Sciences | Phase 1/2 | PLK4 |